Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. Subjective descriptions of cataplexy can assist in the identification of narcolepsy, as this feature is all but unique to the disorder. Unfortunately, cataplexy is challenging to identify, often going undetected. While 19% of patients diagnosed with narcolepsy also get diagnosed with cataplexy, estimates are that roughly 70% of patients with narcolepsy also have cataplexy.
Type 1 narcolepsy (historically known as narcolepsy with cataplexy) is due to a deficiency of orexin-A, a wakefulness-promoting peptide neurotransmitter. There is a near-perfect association of Type 1 narcolepsy with HLA-DQB1*06:02, leading to the auto-immune hypothesis, which posits a selective, self-destruction of orexin-A producing neurons as the driving force behind the disorder. The onset of narcolepsy is seasonal, most often surfacing in the Spring, following upper respiratory tract infections that had occurred in the preceding months . Moreover, there was an increased incidence of narcolepsy following the use of the 2009 European Pandemrix vaccination, suggesting the involvement of molecular mimicry in the development of this disorder.
Secondary narcolepsy, on the other hand, is due to the development of lateral hypothalamic lesions. Although rare, lesions secondary to arteriovenous malformations, cerebrovascular accidents, inflammatory processes, and neoplasms result in the destruction of orexin-A producing neurons. It is worth noting that other neurological deficits are often evident in individuals who develop secondary narcolepsy, as lesions are not typically confined to the lateral hypothalamus.
In the U.S., narcolepsy affects 1 in 2000 individuals with an equal distribution amongst the sexes. Symptom onset most frequently occurs during adolescence; however, diagnosis often gets delayed on average by 15 years. Two forms of narcolepsy exist: Type 1 is associated with cataplexy while this feature is absent in Type 2. In the U.S., Type 1 narcolepsy affects 1 to 2 in 4000 individuals.
In addition to the physical feature of cataplexy, Type 1 narcolepsy further distinguishes from Type 2 narcolepsy on the molecular level. In patients with Type 1 narcolepsy, the examination of cerebrospinal fluid demonstrates decreased levels of orexin-A, a wakefulness-promoting peptide neurotransmitter . Neurons located in the lateral hypothalamus produce orexin-A; it potentiates the production of the following neurotransmitters: Dopamine, histamine, norepinephrine, and serotonin, leading to the suppression of rapid eye movement (REM) sleep. Intense emotions transmitted from the medial prefrontal cortex to the amygdala, in conjunction with the loss of orexin-A, decrease inhibitory signals of REM sleep, ultimately inhibiting motor neurons in the pons, leading to muscle paralysis and cataplexy.
Obtaining an accurate and detailed history is imperative in the diagnosis of narcolepsy. The clinician should perform an investigation of behavioral (i.e., caffeine use, insufficient sleep, poor sleep hygiene, tobacco abuse, etc.) and alternative diagnoses (i.e., anemia, hypothyroidism, obstructive sleep apnea, etc.) of excessive daytime sleepiness. It is essential to realize that patients with narcolepsy are well-rested following a brief nap or sufficient nights' sleep; however, the symptoms of excessive daytime sleepiness occur within hours of awakening. In addition to excessive daytime sleepiness, patients with Type 1 narcolepsy experience symptoms of disordered regulation of REM sleep (i.e., cataplexy, hypnagogic hallucinations, and sleep paralysis).
The sudden onset of muscle weakness characterizes cataplexy. Such episodes are transient, lasting seconds to minutes, and get precipitated by intense emotions. Cataplectic attacks are more frequently incited by positive emotions (i.e., laughter, excitement, etc.) than negative emotions (i.e., anger, fear, frustration, etc.), with laughter being the most common precipitant. It is the complete or partial paralysis of voluntary muscles that is responsible for the weakness associated with cataplexy; however, it bears noting that the muscles of eye movement and respiration get spared during these attacks. The suppression of serotonergic and noradrenergic neuronal circuits permit the complete or partial paralysis of voluntary muscles. Consciousness, however, is uncompromised during cataplectic attacks as wake-promoting histaminergic signaling is preserved. Cataplectic attacks typically follow a crescendo pattern, first involving the muscles of the face and neck with progression to the muscles of the trunk and limbs. Physical findings depend on the severity of each episode, ranging from facial drooping and slurring of speech (partial attacks) to collapse (complete attacks). Episodes of cataplexy often resolve within two minutes, and those afflicted are without lingering effects.
The diagnosis of Type 1 narcolepsy requires the subjective complaint of excessive daytime sleepiness (occurring daily for a minimum of 3 months) in addition to either decreased CSF concentrations of orexin-A or cataplexy in conjunction with the following findings on a multiple sleep latency testing: Mean sleep latency less than or equal to 8 minutes and greater than or equal to 2 sleep-onset REM sleep periods.
While behavior modifications (i.e., planned naps, a sufficient nights' sleep) play a role in the management of the excessive daytime sleepiness associated with Type 1 narcolepsy, treatment of cataplexy is purely pharmacological. The duration of therapy is indefinite, as Type 1 narcolepsy is incurable. It bears mentioning that treatment options include various combinations of medications, often creating an individualized treatment. Clinicians can use the Epworth Sleepiness Scale to follow the response to treatment. For completeness, the pharmacologic treatment of Type 1 narcolepsy, as a whole, is presented below:
Successful management of excessive daytime sleepiness often requires the use of wakefulness-promoting agents, as behavioral modifications fail to provide complete relief. Modafinil (100 to 400 mg by mouth once daily every morning) and its isolated R-enantiomer, armodafinil (150 to 250 mg by mouth once daily every morning), are considered first-line pharmacologic agents in the management of excessive daytimes sleepiness. While the mechanism of action of these agents is not entirely understood, the thinking is that their effects are due to an increase in dopaminergic signaling via the inhibition of dopamine reuptake. Two medications received FDA-approval in 2019: pitolisant and solriamfetol. Pitolisant (8.9 to 35.6 mg by mouth once daily every morning) is a histamine-3 receptor inverse agonist, while solriamfetol (75 to 300 mg by mouth once daily every morning) is a selective dopamine/norepinephrine reuptake inhibitor. For breakthrough excessive daytime sleepiness, the following agents are options on an as-needed basis: Dextroamphetamine-amphetamine (5 to 60 mg by mouth daily in one to three divided doses) and methylphenidate (5 to 60 mg by mouth daily in two to three divided doses).
Successful management of cataplexy requires the use of REM sleep-suppressing drugs. Such agents increase the concentration of norepinephrine and serotonin. The following pharmacologic agents are considered first-line in the management of cataplexy: Selective serotonin reuptake inhibitors (Fluoxetine 10 to 80 mg by mouth daily every morning), Norepinephrine reuptake inhibitors (Atomoxetine 40 to 80 mg by mouth daily every morning), Serotonin/norepinephrine reuptake inhibitors (Venlafaxine extended-release 37.5 to 150 mg by mouth once daily every morning), and tricyclic antidepressants (Clomipramine 10 to 150 mg by mouth daily every morning). Prescribers of the medications, as mentioned earlier, should keep in mind the following considerations:
Currently, only one medication has FDA-approval for the treatment of both cataplexy and the excessive daytime sleepiness associated with narcolepsy: Sodium oxybate, the sodium salt of gamma-hydroxybutyrate. The mechanism of action of this medication is unknown; however, it is a known metabolite of gamma-aminobutyric acid (GABA). It is therefore thought to work via the GABA-B receptor. This medication is dosed initially at bedtime with subsequent dosing 2.5 to 4 hours later and has a significant salt content of 1100 mg to 1640 mg when dosed in the effective range (6 g to 9 g per night in two divided doses).
The management of Type 1 narcolepsy in children differs slightly from management in adults. In children, the first-line pharmacologic agents for the treatment of symptoms of excessive daytime sleepiness are stimulants such as dextroamphetamine-amphetamine (10 to 40 mg by mouth daily in one to two divided doses) or methylphenidate (10 to 60 mg by mouth daily in two to three divided doses) rather than wakefulness-promoting agents such as armodafinil (50 to 250 mg by mouth once daily every morning) and modafinil (50 to 200 mg by mouth once daily every morning). Moreover, the first-line pharmacologic agent for the treatment of cataplexy is sodium oxybate (1 to 2 g per night in two divided doses), rather than REM sleep-suppressing drugs, in children over the age of seven. In children under seven with cataplexy requiring treatment, the following REM sleep-suppressing drugs are possible therapies: Clomipramine 25 mg by mouth once daily at bedtime, fluoxetine 5 to 10 mg by mouth once daily, or venlafaxine extended-release 25 mg by mouth once daily.
Cataplexy is all but unique to Type 1 narcolepsy; therefore, the differential diagnosis of this feature is sparse. Pseudocataplexy, a feature of conversion disorder, is characterized by cataplexy-like attacks; however, the other defining characteristics of narcolepsy are often absent.
Although rare, cataplexy can occur in the presence of lateral hypothalamic lesions implicated in the development of secondary narcolepsy. Such lesions may arise in the setting of arteriovenous malformations, cerebrovascular accidents, inflammatory processes, and neoplasms . Again, if cataplexy were to occur in such situations, other neurological deficits will likely be evident, as neuronal destruction does not typically remain confined to the hypothalamus.
Patients must be capable self-advocates, accurately describing their symptoms to the physician, to facilitate the diagnosis of Type 1 narcolepsy. While Type 1 narcolepsy is an incurable neurological disorder, there are treatment options directed towards symptom management. In patients with narcolepsy with cataplexy, multiple individual pharmacological agents exist for symptomatic management of cataplexy and excessive daytime sleepiness alone, except sodium oxybate, which targets all features of Type 1 narcolepsy.
Severe episodes of cataplexy resulting in complete collapse can result in musculoskeletal injury and intracranial hemorrhage. Factors determining the severity of sequela following a cataplectic fall include age, ground-surface composition, height, pre-existing metabolic bone disease, and surrounding objects.
Cataplexy, a physical feature of narcolepsy, is characterized by transient episodes of voluntary muscle weakness precipitated by intense emotion. It is all but unique to Type 1 narcolepsy, a disorder due to a deficiency of orexin-A, a wakefulness-promoting peptide neurotransmitter. Although incurable, multiple individual pharmacological agents exist for symptomatic management of cataplexy and excessive daytime sleepiness. As this disorder is underdiagnosed, it is crucial that patients are active self-advocates and accurately describing their symptoms to health care providers. While the primary care physician is responsible for conducting the preliminary investigation of a patient's symptoms, the diagnosis of Type 1 narcolepsy and subsequent management requires an interprofessional team, including the consultation of a board-certified sleep medicine physician. To ensure improved outcomes, the pharmacist should educate the patient on medication compliance, as well as verifying dosing and checking for interactions to alert the prescriber. Finally, the medications used to treat cataplexy do have serious adverse effects, and a dedicated nurse must closely monitor the patients. Open communication between the interprofessional team members is vital to ensure good outcomes. [Level V]
|||Scammell TE, Narcolepsy. The New England journal of medicine. 2015 Dec 31; [PubMed PMID: 26716917]|
|||Wren BW,Clayton CL,Mullany PP,Tabaqchali S, Molecular cloning and expression of Clostridium difficile toxin A in Escherichia coli K12. FEBS letters. 1987 Dec 10; [PubMed PMID: 2961615]|
|||Dauvilliers Y,Siegel JM,Lopez R,Torontali ZA,Peever JH, Cataplexy--clinical aspects, pathophysiology and management strategy. Nature reviews. Neurology. 2014 Jul; [PubMed PMID: 24890646]|
|||Rogers AE,Meehan J,Guilleminault C,Grumet FC,Mignot E, HLA DR15 (DR2) and DQB1*0602 typing studies in 188 narcoleptic patients with cataplexy. Neurology. 1997 Jun; [PubMed PMID: 9191765]|
|||Mahlios J,De la Herrán-Arita AK,Mignot E, The autoimmune basis of narcolepsy. Current opinion in neurobiology. 2013 Oct; [PubMed PMID: 23725858]|
|||Han F,Lin L,Warby SC,Faraco J,Li J,Dong SX,An P,Zhao L,Wang LH,Li QY,Yan H,Gao ZC,Yuan Y,Strohl KP,Mignot E, Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Annals of neurology. 2011 Sep; [PubMed PMID: 21866560]|
|||Ahmed SS,Volkmuth W,Duca J,Corti L,Pallaoro M,Pezzicoli A,Karle A,Rigat F,Rappuoli R,Narasimhan V,Julkunen I,Vuorela A,Vaarala O,Nohynek H,Pasini FL,Montomoli E,Trombetta C,Adams CM,Rothbard J,Steinman L, Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2. Science translational medicine. 2015 Jul 1; [PubMed PMID: 26136476]|
|||Aldrich MS,Naylor MW, Narcolepsy associated with lesions of the diencephalon. Neurology. 1989 Nov; [PubMed PMID: 2812331]|
|||Schwartz WJ,Stakes JW,Hobson JA, Transient cataplexy after removal of a craniopharyngioma. Neurology. 1984 Oct; [PubMed PMID: 6541312]|
|||Thorpy MJ,Krieger AC, Delayed diagnosis of narcolepsy: characterization and impact. Sleep medicine. 2014 May; [PubMed PMID: 24780133]|
|||Longstreth WT Jr,Koepsell TD,Ton TG,Hendrickson AF,van Belle G, The epidemiology of narcolepsy. Sleep. 2007 Jan; [PubMed PMID: 17310860]|
|||Feresiadou A,Nilsson K,Ingelsson M,Press R,Kmezic I,Nygren I,Svenningsson A,Niemelä V,Gordh T,Cunningham J,Kultima K,Larsson A,Burman J, Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease. Journal of neuroimmunology. 2019 Jul 15; [PubMed PMID: 30928869]|
|||Overeem S,van Nues SJ,van der Zande WL,Donjacour CE,van Mierlo P,Lammers GJ, The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep medicine. 2011 Jan; [PubMed PMID: 21145280]|
|||Burgess CR,Scammell TE, Narcolepsy: neural mechanisms of sleepiness and cataplexy. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2012 Sep 5; [PubMed PMID: 22956821]|
|||Pizza F,Antelmi E,Vandi S,Meletti S,Erro R,Baumann CR,Bhatia KP,Dauvilliers Y,Edwards MJ,Iranzo A,Overeem S,Tinazzi M,Liguori R,Plazzi G, The distinguishing motor features of cataplexy: a study from video-recorded attacks. Sleep. 2018 May 1; [PubMed PMID: 29425380]|
|||Schneider L,Mignot E, Diagnosis and Management of Narcolepsy. Seminars in neurology. 2017 Aug; [PubMed PMID: 28837992]|
|||Nishino S,Okuro M, Armodafinil for excessive daytime sleepiness. Drugs of today (Barcelona, Spain : 1998). 2008 Jun; [PubMed PMID: 18596995]|
|||Barateau L,Dauvilliers Y, Recent advances in treatment for narcolepsy. Therapeutic advances in neurological disorders. 2019; [PubMed PMID: 31632459]|
|||Dauvilliers Y,Barateau L, Narcolepsy and Other Central Hypersomnias. Continuum (Minneapolis, Minn.). 2017 Aug; [PubMed PMID: 28777172]|
|||Kerr GW,McGuffie AC,Wilkie S, Tricyclic antidepressant overdose: a review. Emergency medicine journal : EMJ. 2001 Jul; [PubMed PMID: 11435353]|
|||Bartlett D, Drug-Induced Serotonin Syndrome. Critical care nurse. 2017 Feb; [PubMed PMID: 28148614]|
|||Matos N,Gaig C,Santamaria J,Iranzo A, Cataplexy causing subdural hematomas. Sleep medicine. 2017 Feb; [PubMed PMID: 28215239]|